Miss Molly Moon takes on Munich for AIDS 2024

July 22 - 26, 2024 | Munich, Germany

Brian Minalga and Miss Molly Moon represented HANC at AIDS 2024. Miss Molly appeared at the HPTN/HVTN booth in the Global Village, where she was interviewed by Dr. Asa Radix about trans and gender-diverse inclusion in HIV research.

On Day 3 of the conference, Brian provided media coverage on HIV.gov, interviewing the likes of Carl Dieffenbach (DAIDS), Tori Cooper (PACHA), and Jono Mermin (CDC) on topics such as lenacapavir for HIV prevention, the inclusion of people who use drugs in HIV research, and leveraging the power of the DAIDS-funded HIV research Networks to address global pandemics.

AIDS 2024 was an amazing opportunity to connect with our colleagues and friends in the HIV response, and we look forward to seeing you again soon!


Exclusive Interviews with Director of DAIDS Dr. Carl Dieffenbach and Other Experts

HANC Deputy Director Brian Minalga interviews Director of DAIDS, Dr. Carl Dieffenbach and catches up on the PURPOSE 1 study results, representation of people who use drugs in clinical trials, and future vision for HIV research.

We can't stop talking about Lenacapavir at AIDS 2024!

HANC Deputy Director Brian Minalga gets the scoop in Munich.

“Trans people, and trans men specifically, have been left behind in the HIV response for far too long. This is the first time a trans man has been given the opportunity to speak at the IAS opening. As a trans man from Uganda, I am so grateful for this opportunity. May we continue to hear voices from my community so I am not the only one.”

Jay Mulucha

Twice-yearly Lenacapavir or Daily Oral Entricitabine/Tenofovir for HIV Prevention in Cisgender Women: Interim Analysis Results from the PURPOSE 1 Study

PURPOSE 1 Study Design
PURPOSE 1 Study Design
ZERO HIV Infections in Cisgender Women receiving LEN
ZERO HIV Infections in Cisgender Women receiving LEN
Secondary Analysis
Secondary Analysis
PURPOSE 1 Conclusions
PURPOSE 1 Conclusions

Miss Molly Moon and Friends at AIDS 2024